Document is current
Any future updates will be listed below
-
Authors
Smabers, Lidwien P. https://orcid.org/0009-0007-9631-1012
Nienhuis, Hilde H.
de Leng, Wendy W. J.
Roepman, Paul
Ciftcibasi, Ilcan Ö. A.
Wensink, G. Emerens
Huismans, Maarten A.
Valkenburg-van Iersel, Liselot B. J. https://orcid.org/0000-0003-2925-9908
Cirkel, Geert A.
Gootjes, Elske C.
Verheul, Henk M. W.
Jeurissen, Frank J.
Bol, Guus M.
Kranenburg, Onno https://orcid.org/0000-0002-2112-4390
Koopman, Miriam https://orcid.org/0000-0003-1550-1978
Cuppen, Edwin https://orcid.org/0000-0002-0400-9542
Roodhart, Jeanine M. L.
- License Information
-
More Information
Article History
Received: 10 June 2025
Revised: 24 September 2025
Accepted: 23 October 2025
First Online: 7 November 2025
Competing interests
: HN reports advisory positions subsidized by Bayer, Roche and J&J. She resports educational activities subsidized by Bayer, J&J and Illumina. LV reports financial interests with and an advisory role for Servier and Pierre Fabre. All grants were unrelated to the study and paid to individual’s institutions. All other authors declare that they have no competing interests. GB reports institutional scientific grants from Pierre Fabre and Terumo. MK reports institutional financial interests with Amgen, Bayer, Bristol-Myers Squibb, Merck-Serono, Nordic Pharma, Pierre Fabre, Servier, Sirtex, Roche, Sanofi, and Personal Genome Diagnostics. She reports the following non-financial interests: an advisory role for ZON-MW, membership of the scientific board of the Dutch Cancer Society (KWF), chairmanship of the Dutch Colorectal Cancer Group (DCCG), and principal investigator (PI) of the Prospective Dutch Colorectal Cancer (PLCRC) cohort. EC is initiator and scientific director of the Hartwig Medical Foundation. JR reports institutional financial interests with BMS, Pierre Fabre, Servier, Cleara, Xilis, DoMore diagnostics and HUB organoids B.V. JR reports an advisory role for Bayer, BMS, Merck-Serono, Pierre Fabre, Servier, AMGEN and board member of Foundation Hubrecht Organoid Biobank.
: This research was performed under the OPTIC protocol. The medical ethical committee of the University Medical Center Utrecht (UMCU) approved the OPTIC trial (NL61668.041.17). The study was performed in accordance with the Declaration of Helsinki. All patients provided written informed consent.
